Forbion raises €200m for biotech fund

Forbion raises €200m for biotech fund

Forbion raises €200 million for sustainable biotech investments. The Netherlands-based venture capital firm Forbion has secured €200 million for its Forbion BioEconomy Fund I, exceeding its €150 million target. The fund focuses on biology-based industrial sustainability solutions across Europe and North America….


Forbion, a Netherlands-based venture capital firm specialising in life sciences, has announced the successful raising of €200 million in commitments for its Forbion BioEconomy Fund I. This fund aims to invest in companies offering biology-based solutions for industrial sustainability. The fund’s closing at €200 million surpassed its initial target of €150 million, marking a significant achievement for Forbion.

Key investors in the fund include KfW Capital, Novo Holdings, Rentenbank, Aurae Impact, ABN AMRO Bank, and EIFO. Alexander Hoffmann, General Partner at Forbion, highlighted the growing confidence in science-led solutions to address global challenges, stating that biotechnology is expanding beyond healthcare into sectors such as food, materials, and resource efficiency.

Launched in 2024, the Forbion BioEconomy Fund I is dedicated to investing in biotechnologies and green chemistries that promote scalable industrial sustainability. It targets companies developing sustainable technologies within four priority sectors: Food, Agriculture, Materials, and Environmental Technologies. The fund plans to build a portfolio of 12-14 investments primarily in Series A and B stage companies across Europe and North America. These companies are expected to offer cost-effective and scalable biology-based business-to-business solutions that have demonstrated proof of concept, aiming to replace existing products at competitive prices.

To date, the fund has invested in five companies, including eeden, a green chemistry-based textile recycling company; Genomines, specialising in biotechnology-based valuable metals extraction; SOLASTA Bio, a provider of bio-based pesticide alternatives; Novameat, a plant-based proteins company; and PACT, a biomaterials platform.

Joy Faucher, another General Partner at Forbion, commented on the shift in capital from software to science. She expressed enthusiasm about building a portfolio backed by leading institutional and strategic partners, leveraging biology and chemistry to deliver sustainable and commercially viable solutions for the planet.



  • ExtraHop unveils new agentic SOC capabilities

    ExtraHop unveils new agentic SOC capabilities

    ExtraHop launches new tools to power agentic security operations. The network detection and response company has introduced enhanced visibility, identity integrations, and Kubernetes telemetry capabilities designed to provide AI agents within security operations centres with the contextual data required to operate autonomously and respond to advanced threats at machine speed.


  • US court blocks expanded merger disclosure rule

    Federal judge halts expanded US merger disclosure requirements. A Texas court has blocked a rule that would have significantly broadened the information companies must provide in US merger filings, marking a setback for federal antitrust regulators and creating fresh uncertainty around the future direction of disclosure reform.


  • KKR-Arctos deal transcends private equity growth

    KKR-Arctos deal transcends private equity growth

    KKR acquires Arctos Partners for $1.4bn, reshaping private equity. The acquisition offers immediate access to a diversified sports portfolio and highlights a shift in private equity towards more sophisticated structures and governance amid increasing regulatory scrutiny.